Body habitus in a cohort of HIV-seropositive and HIV-seronegative injection drug users

AIDS Patient Care and STDs

Volumn 19, Issue 1, 2005, Pages 19-30

  Smit, Ellen ^a   Semba, Richard D ^b   Pilibosian, Erin ^c   Vlahov, David ^c,d   Tun, Waimar ^c   Purvis, Lisa ^e   Tang, Alice M ^f  

^a UNIVERSITY AT BUFFALO   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d NEW YORK ACADEMY OF MEDICINE   (United States)

^e DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^f TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTHROPOMETRY; ARTICLE; BODY FAT; BODY HEIGHT; BODY MASS; BODY WEIGHT; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DRUG USE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBESITY; SELF REPORT; SERODIAGNOSIS; SKINFOLD THICKNESS; SYMPTOMATOLOGY;

ADULT; AGE DISTRIBUTION; ANTHROPOMETRY; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY COMPOSITION; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROBABILITY; SENSITIVITY AND SPECIFICITY; SEX DISTRIBUTION; SUBSTANCE ABUSE, INTRAVENOUS; SURVIVAL ANALYSIS;

EID: 12844273418     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2005.19.19     Document Type: Article

References (31)

1. Benson JO, McGhee K, Coplan P, et al. Fat redistribution in indinavir-treated patients with HIV infection: A review of postmarketing cases. J Acquir Immune Defic Syndr 2000;25:130-139.
2. Carr A, Emery S, Law M, et al. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003;361:726-735.
3. Gerrior J, Kantaros J, Coakley E, Albrecht M, Wanke C. The fat redistribution syndrome in patients infected with HIV: Measurements of body shape abnormalities. J Am Diet Assoc 2001;101:1175-1180.
4. Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999;13:465-471.
5. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet 1998;351:867-870.
6. Rodwell GE, Maurer TA, Berger TG. Fat redistribution in HIV disease. J Am Acad Dermatol 2000;42(5 Pt 1):727-730.
7. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection [editorial]. AIDS 1999;13:2493-2505.
8. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999;13:1659-1667.
9. Stricker RB, Goldberg B. Fat accumulation and HIV-1 protease inhibitors. Lancet 1998;352:1392.
10. Struble K, Piscitelli SC. Syndromes of abnormal fat redistribution and metabolic complications in HIV-infected patients. Am J Health Syst Pharm 1999;56:2343-2348.
11. Vigouroux C, Gharakhanian S, Salhi Y, et al. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease. Diabetes Metab 1999;25:383-392.
12. Wanke CA. Epidemiological and clinical aspects of the metabolic complications of HIV infection the fat redistribution syndrome. AIDS 1999;13:1287-1293.
13. Tien PC, Cole SR, Williams CM, et al. Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIV study. J Acquir Immune Defic Syndr 2003;34:461-466.
14. Vlahov D, Anthony JC, Munoz A, et al. The Alive Study - A longitudinal-study of HIV-1 infection in intravenous-drug-users - Description of Methods. J Drug Issues 1991;21:759-776.
15. The Third National Health and Examination Survey Reference Manuals and Reports [CD-ROM]. Hyattsville, MD: National Center for Health Statistics, 1996.
16. Durnin JVGA, Womersle J. Body fat assessed from total-body density and its estimation from skinfold thickness - Measurements on 481 men and women aged from 16 to 72 years. Br J Nutr 1974;32:77-97.
17. Kotler DP, Burastero S, Wang J, Pierson RN Jr. Prediction of body cell mass, fat-free mass, and total body water with bioelectrical impedance analysis: Effects of race, sex, and disease [see comments]. Am J Clin Nutr 1996;64(3 Suppl):489S-497S.
18. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289:76-79.
19. Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001;15:1389-1398.
20. Heath KV, Hogg RS, Singer J, et al. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based chort. J Acquir Immune Defic Syndr 2002;30:440-447.
21. Thiebaut R, Daucourt V, Mercie P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidemiologie Clinique du Syndrome d'Immunodeficience Acquise en Aquitaine. Clin Infect Dis 2000;31:1482-1487.
22. Dreezen C, Schrooten W, de M I, et al. Self-reported signs of lipodystrophy by persons living with HIV infection. Int J STD AIDS 2002;13:393-398.
23. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet 1999;353:2093-2099.
24. Guaraldi G, Murri R, Orlando G, et al. Morphologic alterations in HIV-infected people with lipodystrophy are associated with good adherence to HAART. HIV Clin Trials 2003;4:99-106.
25. Bergersen BM, Sandvik L, Bruun JN. Body composition changes in 308 Norwegian HIV-positive patients. Scand J Infect Dis 2004;36:186-191.
26. Greenberg B, Berkman A, Thomas R, et al. Evaluating supervised HAART in late-stage HIV among drug users: A preliminary report. J Urban Health 1999;76:468-480.
27. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med 2002;17:377-381.
28. Worm D, Kirk O, Andersen O, et al. Clinical lipoatrophy in HIV-1 patients on HAART is not associated with increased abdominal girth, hyperlipidaemia or glucose intolerance. HIV Med 2002;3:239-246.
29. Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing anti-retroviral therapy: Preliminary results of the LIPOCO study. AIDS 2000;14:37-49.
30. Saint-Marc T, Touraine JL. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy. AIDS 1999;13:2188-2189.
31. Tsekes G, Chrysos G, Douskas G, et al. Body composition changes in protease inhibitor-naive HIV-infected patients treated with two nucleoside reverse transcriptase inhibitors. HIV Med 2002;3:85-90.